This interview, from May, 2004, contains a frank discussion of what went wrong with COR’s initial Ampakine compound, CX-516, and why the follow-on molecule, CX-717, should work a heck of a lot better. A pretty good overview of this promising --and exceptionally cheap-- company in the CNS arena.
It’s instructive to compare this TWST interview with one from last summer (#msg-3202870) to see just what has changed in the ensuing ten months.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.